Cancer Sci 2020 Dec 7. Epub 2020 Dec 7.
Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
TAS0313, a novel cancer vaccine cocktail, was developed to overcome the disadvantages of previously developed short and long peptide vaccines; it comprises several long peptides targeting multiple cancer antigens. We evaluated TAS0313 monotherapy in Japanese patients with advanced solid tumors for which no other therapies were available. In the dose-finding cohort, patients received TAS0313 (9 mg or 27 mg) on Days 1, 8, and 15 of Cycles 1 and 2, and then on Day 1 of each subsequent 21-day cycle. Read More